Buyer beware: an IP checklist for life sciences investors
This is an Insight article, written by a selected partner as part of IAM's co-published content. Read more on Insight
Whether caused by the paucity of new products in pharma pipelines or the lure of a highly marketable new technology, investors often become comfortable with a deal before effectively evaluating the target’s intellectual property portfolio. IP issues that are overlooked often decrease the value of the investment and open the door for future debilitating litigation.
Download